Antimicrobial susceptibility analysis of isepamicin combination treatments in Mycobacterium abscessus species.
J Clin Tuberc Other Mycobact Dis
; 36: 100464, 2024 Aug.
Article
in En
| MEDLINE
| ID: mdl-39099802
ABSTRACT
This study evaluated the antimicrobial potency of the combination of isepamicin (ISP) for Mycobacterium abscessus species (MABS). 34 clinical MABS strains were isolated from clinical samples. Of them, 11 (32.4 %) were M. abscessus subsp. abscessus (Mab), 22 (64.7 %) were M. abscessus subsp. massiliense (Mma), and one (2.9 %) was M. abscessus subsp. bolletii (Mbo). We compared susceptibility to sitafloxacin (STFX)-ISP and clarithromycin (CLR)-ISP combinations with those of the antimicrobial agents alone, and synergistic effects were observed in 41.2 % and 17.6 % when treated with STFX-ISP and CLR-ISP. By hierarchical cluster analysis, the isolates divided into treatment-sensitive and treatment-resistant groups. Non-Mma or rough colony isolates were significantly likely to belong to the treatment-sensitive group (p = 0.024, p < 0.001, respectively). These results suggest that the ISP-containing combination could be a new therapeutic strategy for MABS, especially in cases of non-Mma treatment-refractory subspecies, and rough morphotypes high-virulence morphotypes.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
J Clin Tuberc Other Mycobact Dis
Year:
2024
Document type:
Article
Affiliation country:
Japón
Country of publication:
Reino Unido